QUANTRES ASSET MANAGEMENT Ltd Purchases 600 Shares of Regeneron Pharmaceuticals Inc (REGN)

QUANTRES ASSET MANAGEMENT Ltd increased its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 50.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,800 shares of the biopharmaceutical company’s stock after purchasing an additional 600 shares during the period. QUANTRES ASSET MANAGEMENT Ltd’s holdings in Regeneron Pharmaceuticals were worth $739,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Whittier Trust Co. raised its holdings in shares of Regeneron Pharmaceuticals by 195.7% in the fourth quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 45 shares during the last quarter. Rehmann Capital Advisory Group raised its holdings in shares of Regeneron Pharmaceuticals by 1,700.0% in the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 68 shares during the last quarter. AdvisorNet Financial Inc raised its holdings in shares of Regeneron Pharmaceuticals by 208.0% in the fourth quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 52 shares during the last quarter. Captrust Financial Advisors acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $30,000. Finally, Intercontinental Wealth Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 67.03% of the company’s stock.

Shares of REGN traded up $1.48 on Friday, hitting $336.89. 810,083 shares of the stock traded hands, compared to its average volume of 748,789. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.47. The company has a market capitalization of $36.65 billion, a price-to-earnings ratio of 17.01, a PEG ratio of 1.33 and a beta of 1.08. Regeneron Pharmaceuticals Inc has a 1 year low of $281.89 and a 1 year high of $442.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $1.74. The business had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.73 billion. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The company’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.23 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals Inc will post 19.92 EPS for the current fiscal year.

A number of research analysts have recently issued reports on the stock. Jefferies Financial Group dropped their price target on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating on the stock in a research note on Wednesday, April 17th. BidaskClub lowered shares of Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 25th. Cantor Fitzgerald reiterated a “hold” rating and set a $441.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, February 6th. Oppenheimer upped their target price on shares of Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the stock an “outperform” rating in a research report on Thursday, February 7th. Finally, BMO Capital Markets upped their target price on shares of Regeneron Pharmaceuticals to $412.00 and gave the stock a “market perform” rating in a research report on Thursday, February 7th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $413.94.

In related news, major shareholder Sanofi sold 131,115 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $412.17, for a total transaction of $54,041,669.55. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 12.42% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “QUANTRES ASSET MANAGEMENT Ltd Purchases 600 Shares of Regeneron Pharmaceuticals Inc (REGN)” was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/05/04/regeneron-pharmaceuticals-inc-regn-stake-raised-by-quantres-asset-management-ltd.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: What is Put Option Volume?

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.